Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$681,050
+$236,220 QoQ
Shares Held
15,879
+56.5% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Derivatives in EXEL
reported options exposure · as of Jun 30, 2022CallValue
$520,500
CallShares
25,000
PutValue
$520,500
PutShares
25,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026CSS LLC/IL holds $14,889,923 across 15 Biotechnology names. EXEL ranks #7 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
79,093 | $5,939,093 | |
| 2 | APLS |
Apellis Pharmaceuticals, Inc.
|
42,818 | $1,722,568 | |
| 3 | INCY |
Incyte Corp
|
12,068 | $1,135,840 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,170 | $903,988 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
15,980 | $902,710 | |
| 6 | ACLX |
Arcellx, Inc.
|
7,600 | $872,632 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
15,879 | $681,050 | |
| 8 | CNTA |
Centessa Pharmaceuticals plc
|
17,000 | $675,240 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $681,050 | 15,879 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $444,830 | 10,149 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $394,373 | 9,549 | Shares | Sole | 2025-11-13 | |
| 2022-06-30 | $520,500 | 25,000 | Put | Sole | 2022-08-15 | |
| 2022-06-30 | $520,500 | 25,000 | Call | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||